Coronary flow reserve and exercise capacity in hypertrophic cardiomyopathy. 1996

P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
Second Department of Cardiology, Collegium Medicum Jagiellonian University, Kraków, Poland.

The aim of this study was to evaluate the relation of coronary flow velocity (CFV) and coronary flow reserve (CFR) to exercise capacity in ten verapamil-treated patients with hypertrophic cardiomyopathy (HC). Using Doppler transesophageal echocardiography, we assessed diastolic CFV in the proximal left anterior descending coronary artery at baseline and after administering 0.56 mg/kg intravenous dipyridamole. The CFR was calculated as the post-dipyridamole/baseline diastolic CFV ratio. A maximal symptom-limited exercise treadmill test was performed according to a modified Bruce protocol and the exercise capacity was expressed as metabolic equivalents. The mean value for baseline diastolic CFV was 59 +/- 27 cm/s; this increased after dipyridamole to 134 +/- 57 cm/s. The CFR was 2.37 +/- 0.67. Baseline diastolic CFV correlated negatively with both exercise duration (r = -0.69; P < 0.05) and value for metabolic equivalents (r = -0.70; P < 0.05). CFR was weakly and non-significantly related to exercise duration (r = 0.40; P > 0.05) and to the value for metabolic equivalents (r = 0.32; P > 0.05). Shortening of exercise time and decreasing metabolic equivalents were correlated with increased baseline diastolic CFV. Dipyridamole-assessed CFR, was weakly related to parameters of exercise capacity.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D001783 Blood Flow Velocity A value equal to the total volume flow divided by the cross-sectional area of the vascular bed. Blood Flow Velocities,Flow Velocities, Blood,Flow Velocity, Blood,Velocities, Blood Flow,Velocity, Blood Flow
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D014700 Verapamil A calcium channel blocker that is a class IV anti-arrhythmia agent. Iproveratril,Calan,Cordilox,Dexverapamil,Falicard,Finoptin,Isoptin,Isoptine,Izoptin,Lekoptin,Verapamil Hydrochloride,Hydrochloride, Verapamil

Related Publications

P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
October 1987, International journal of cardiology,
P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
February 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography,
P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
January 2015, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese,
P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
December 1983, Journal of cardiography,
P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
April 2013, Clinical cardiology,
P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
September 2000, European journal of nuclear medicine,
P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
May 1998, Clinical science (London, England : 1979),
P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
July 2022, International journal of cardiology,
P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
January 1992, Journal of cardiology,
P P Dimitrow, and M Krzanowski, and W Bodzoń, and A Szczeklik, and J S Dubiel
February 2004, Kardiologia polska,
Copied contents to your clipboard!